Mark Alan Smith's most recent trade in VistaGen Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on June 30, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics Inc | Mark Alan Smith | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.75 per share. | 30 Jun 2022 | 5,000 | 19,915 (0%) | 0% | 0.7 | 3,740 | Common Stock |
| VistaGen Therapeutics Inc | Mark Alan Smith | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Mark Alan Smith | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 1.95 per share. | 30 Jun 2021 | 2,260 | 12,260 (0%) | 0% | 1.9 | 4,399 | Common Stock |